On today's Cannabis Boomer's Journal of News and Reviews in Cannabis Science, Dr. Alex Terrazas PhD gives his take on the latest findings in cannabis research. Florida Moves to Restrict Medical Marijuana Use in Vehicles A new bill has been introduced in the Florida Senate that aims to crack down on the transportation of open cannabis products. The proposed legislation would make it illegal for both drivers and passengers to have open containers of medical marijuana, hemp, or THC-infused products in their vehicles. Patient advocates warn that it could create significant hardships for the state's nearly 1 million registered medical marijuana users. DEA Delays Cannabis Rescheduling Decision Despite Executive Order The Drug Enforcement Administration has confirmed that the process to reschedule cannabis remains in limbo, despite a recent executive order from President Trump directing the attorney general to complete the reform "in the most expeditious manner." The delay stands in contrast to the DEA's moves to increase production quotas for psychedelics like psilocybin and DMT. Delaware Decriminalizes Public Marijuana Smoking The state of Delaware has passed a bill that decriminalizes the public consumption of marijuana. Individuals caught smoking marijuana in public will face a civil fine of $100, rather than criminal charges. Supporters of the bill argue that this move will help address racial disparities in marijuana-related arrests and destigmatize the use of the drug. Real-world efficacy and safety of CBD in developmental and epileptic encephalopathies This study found that CBD was effective in reducing seizure frequency across various developmental and epileptic encephalopathies, including off-label indications, and was generally well-tolerated, with adverse events being mostly mild to moderate in severity. Rethinking Alzheimer's: Harnessing CBD to Modulate I D O and c GAS Pathways for Neuroinflammation Control This study investigated how CBD independently influences two key neuroinflammatory regulators in Alzheimer's disease. The findings support CBD as a potential monotherapy or adjunctive treatment for Alzheimer's Disease by targeting distinct neuroinflammatory pathways. CBD as a multifaceted therapeutic agent: mitigating Alzheimer's disease pathology and enhancing cognitive function This research article explores the potential of CBD as a therapeutic agent for Alzheimer's disease, focusing on its ability to mitigate disease pathology and enhance cognitive function. The key findings indicate that CBD exhibits neuroprotective effects, reduces neuroinflammation, and improves cognitive performance in Alzheimer's disease models. #CannabisBoomer

#THC #CBD #CannabisScience #MedicalMarijuana #Alzheimer'sDisease #Epilepsy #CBD #DEA #Rescheduling #PublicConsumption #Florida #Delaware #Research #Science #BabyBoomers #OlderAdults

Grace 0:0:0

On today's Cannabis Boomer's Journal of News and Reviews in Cannabis Science, Dr. Alex Terrazas PhD gives his take on the latest findings in cannabis research.

But first. here is The Cannabis Boomer's top cannabis news story.

Alex Terrazas, PhD: The Cannabis Boomer 0:0:19

And here are your top cannabis stories for January 7th.

Florida Moves to Restrict Medical Marijuana Use in Vehicles

In a move that could impact thousands of medical marijuana patients in the Sunshine State, a new bill has been introduced in the Florida Senate that aims to crack down on the transportation of open cannabis products. The proposed legislation, filed by Fort Myers Republican Sen. Jonathan Martin, would make it illegal for both drivers and passengers to have open containers of medical marijuana, hemp, or THC-infused products, including beverages, in their vehicles.

Under the bill, law enforcement would be granted the authority to search vehicles based on the "plain smell" of these substances, effectively overriding a recent court ruling that the smell of marijuana alone is not sufficient grounds for a search. Violators could face penalties ranging from noncriminal traffic violations to the suspension or even permanent revocation of their medical marijuana identification cards, which are required to legally purchase these products.

The bill's sponsor, Sen. Martin, argues that this measure is necessary to address public safety concerns. However, patient advocates warn that it could create significant hardships for the state's nearly 1 million registered medical marijuana users, who rely on these treatments for a variety of health conditions. As the debate over this legislation continues, the delicate balance between public safety and patient access to essential medicine remains a central focus.

Alex Terrazas, PhD: The Cannabis Boomer 0:2:5

And this just in from Washington.

DEA Delays Cannabis Rescheduling Decision Despite Executive Order

The Drug Enforcement Administration has confirmed that the process to reschedule cannabis remains in limbo, despite a recent executive order from President Trump directing the attorney general to complete the reform "in the most expeditious manner." In a new filing, the DEA stated that the marijuana rescheduling appeal is still "pending" and on hold, leaving the future of federal cannabis policy in uncertainty.

This development comes as a disappointment to the cannabis industry and legalization advocates, who had hoped the executive order would spur swift action on rescheduling. The delay also stands in contrast to the DEA's moves to increase production quotas for psychedelics like psilocybin and DMT, signaling a continued cautious approach to reforming the federal treatment of cannabis.

Meanwhile, the battle over cannabis legalization continues to play out at the state level. In Florida, the attorney general and business groups have filed briefs urging the state's Supreme Court to block a legalization initiative from appearing on the November ballot. And in Pennsylvania, lawmakers are calling for responsible regulation of the drug to generate revenue and strengthen the economy. As the patchwork of state laws grows, the federal government's indecision on rescheduling leaves the industry and consumers in limbo.

Alex Terrazas, PhD: The Cannabis Boomer 0:3:51

Finally, from Delaware, a surprising move on public cannabis smoking:

Delaware Decriminalizes Public Marijuana Smoking

In a significant move, the state of Delaware has passed a bill that decriminalizes the public consumption of marijuana. This landmark legislation marks a shift in the state's approach to cannabis, reflecting the growing acceptance of the drug across the country.

Under the new law, individuals caught smoking marijuana in public will face a civil fine of $100, rather than criminal charges. This change is expected to reduce the burden on the criminal justice system and provide a more compassionate approach to those who choose to use the drug. Supporters of the bill argue that this move will help address racial disparities in marijuana-related arrests, which have disproportionately affected minority communities.

The decriminalization of public marijuana smoking is part of a broader trend in the United States, as more states move towards legalizing and regulating the use of cannabis. While Delaware has not yet legalized the recreational use of marijuana, this latest development is seen as a step in that direction. Proponents of the bill believe that it will also help to destigmatize the use of the drug, which has been shown to have potential medical benefits, including the treatment of chronic pain, anxiety, and seizures through the use of CBD and THC.

Grace 0:5:26

And now the Cannabis Boomer reviews recent cannabis science publications.

Alex Terrazas, PhD: The Cannabis Boomer 0:5:31

For our science review, we have an article about CBD and epilepsy:

Real-world efficacy and safety of CBD in developmental and epileptic encephalopathies. by Perulli and others in Epilepsia.

This study aimed to assess the real-world use, efficacy, and safety of CBD across a broad cohort of patients with developmental and epileptic encephalopathies, including off-label indications.

The key findings were that CBD was effective in reducing seizure frequency across various developmental and epileptic encephalopathies, including off-label indications, and was generally well-tolerated, with adverse events being mostly mild to moderate in severity.

The study was a retrospective analysis of medical records from patients with developmental and epileptic encephalopathies who were prescribed CBD. Seizure frequency, adverse events, and other clinical outcomes were assessed.

The findings suggest that CBD may be a valuable treatment option for patients with developmental and epileptic encephalopathies, including those with off-label indications, and provide important real-world data on its use and safety.

The retrospective nature of the study and the lack of a control group are limitations that should be considered when interpreting the results.

Alex Terrazas, PhD: The Cannabis Boomer 0:7:5

And next is this interesting paper about Alzheimer's Disease and Neuroinflamation:

Rethinking Alzheimer's: Harnessing CBD to Modulate I D O and c GAS Pathways for Neuroinflammation Control. by Emami Naeini and others in eNeuro.

This study investigates how CBD independently influences two key neuroinflammatory regulators in Alzheimer's disease.

CBD treatment significantly reduced inflamatory expression, correlating with decreased proinflammatory cytokines. Bioinformatics identified potential interactions between CBD and immune targets.

The researchers administered CBD via inhalation to mice and assessed neuroinflamatory expression using flow cytometry, immunofluorescence, and gene expression analysis. They also evaluated cytokine levels and used bioinformatics to identify CBD-target interactions.

These findings support CBD as a potential monotherapy or adjunctive treatment for Alzheimer's Disease by targeting distinct neuroinflammatory pathways.

Further studies are warranted to fully explore the therapeutic potential of CBD, and the study's use of a single mouse model and administration route may limit the generalizability of the findings.

Alex Terrazas, PhD: The Cannabis Boomer 0:8:34

And in another publication about Alzheimer's Disease, we have:

CBD as a multifaceted therapeutic agent: mitigating Alzheimer's disease pathology and enhancing cognitive function. by Raïch and others in Alzheimer's research & therapy

This research article explores the potential of CBD as a therapeutic agent for Alzheimer's disease, focusing on its ability to mitigate disease pathology and enhance cognitive function.

The key findings indicate that CBD exhibits neuroprotective effects, reduces neuroinflammation, and improves cognitive performance in Alzheimer's disease models.

The study employed in vitro and in vivo experiments, including cell culture assays and animal models, to investigate the mechanisms by which CBD exerts its therapeutic effects.

The clinical and practical implications of this research suggest that CBD may be a promising candidate for the development of novel treatments for Alzheimer's disease.

The study's methodological limitations include the use of animal models, which may not fully capture the complexity of human Alzheimer's disease, and the need for further clinical trials to validate the findings.

Michael 0:9:55

You've been listening to The Cannabis Boomer's Journal of News and Reviews in Cannabis Science. The Cannabis Boomer Podcast is not just for baby boomers and older adults but for all adults who are interested in the science of cannabis and health. Join the Cannabis Boomer daily for these concise scientific reviews and visit The Cannabis Boomer Podcast for in-depth looks and interviews.

#THC #CannabisBoomer #CannabisScience #MedicalMarijuana #Alzheimer'sDisease #Epilepsy #CBD #DEA #Rescheduling #PublicConsumption #Florida #Delaware #Research #Science #BabyBoomers #OlderAdults